These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32752585)

  • 1. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
    Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
    Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
    Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A
    J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
    Soman B; Dias MC; Rizvi SAJ; Kardos A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
    Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
    J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma.
    Newman MT; Bikhchandani M
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2140. PubMed ID: 39041627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
    Yu H; Wang X; Pan Y; Li H
    J Neurol; 2024 Aug; 271(8):5326-5332. PubMed ID: 38864881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
    Lara MS; Afify A; Ellis MP; Phan CT; Richman DP; Riess JW
    Clin Lung Cancer; 2019 Jul; 20(4):e489-e491. PubMed ID: 31085042
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
    Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 15. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
    J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic complications of immune checkpoint inhibitors.
    Haugh AM; Probasco JC; Johnson DB
    Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
    Leaver PJ; Jang HS; Vernon ST; Fernando SL
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
    Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.